Bausch Health Companies Inc.

NYSE:BHC

Drug Manufacturers - Specialty & Generic

Healthcare
$8.73 -2.21%

-$0.11 today

Market cap
$3.27B
Beta
0.41
P/E (TTM)
-1.5
EPS (TTM)
-$3.19
52W Low $4.57High $8.69

Volume 6.83M

Average 1.70M

BHC Purchases of Investments

Cash used to buy marketable securities and other investments.

Bausch Health Companies Inc.NYSE: BHC

Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026

Purchases of investments growth accelerates

Q2 FY2026 purchases of investments of $5M (cash outflow) rose 400.0% year over year, ahead of the -49.7% change in trailing-twelve-month purchases of investments. Sequentially, it rose 400.0% from the prior quarter. Over 3 fiscal years it compounded at -13.5% a year.

Context

  • Purchases of investments amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +400.0% holds above the trailing-twelve-month pace of -49.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$5M+400.0% QoQ
Last fiscal yearDec 2025
-$11M-8.3% YoY
LTMJun 2026
-$12.08M-49.7% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+400.0%——
1 year-8.3%——
3-year CAGR-13.5%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(11M) USD
Year-over-year change
+8.3%

Purchases of Investments vs competitors

How BHC compares with its peers on the latest reported figures

  • BHC's LTM Jun 2026 purchases of investments of $12.08M is the 4th largest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -49.7% is the lowest of 6, against a peer median of +100.0%.
  • Purchases of investments amounts to 0.1% of revenue for BHC, versus a peer median of 0.0%.
BHC Competitors Peer median
Purchases of Investments for BHC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$1.23B +232.8%+124.8%—
BEAMBeam Therapeutics Inc.LTM Jun 2026$871.39M +5.0%-9.2%558.5%
ALVOAlvotechLTM Mar 2026$31.66M ——5.7%
BHCBausch Health Companies Inc.LTM Jun 2026$12.08M -49.7%-13.5%0.1%
HAEHaemonetics CorporationLTM Jun 2026$9.08M +125.8%—0.7%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$0 ——0.0%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
HCMHUTCHMED (China) LimitedLTM Jun 2025$0 +100.0%+31.8%0.0%
PRGOPerrigo Company plcLTM Jun 2026$0 ——0.0%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$0 +100.0%—0.0%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding BHC) $0+100.0%+31.8%0.0%

Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(937M)(212M)(611M)(72M)120M
Depreciation & Amortization1.55B1.39B1.26B1.27B1.21B
Deferred Income Tax(225M)(176M)51M66M80M
Stock-Based Compensation128M126M132M150M216M
Change in Working Capital(128M)(396M)(582M)7M(222.83M)
Accounts Receivables(229M)(57M)(195M)(216M)(136.35M)
Inventory(16M)(198M)(322M)(267M)(12.21M)
Accounts Payables121M(75M)158M357M(77.33M)
Other Working Capital(4M)(66M)(223M)133M3.05M
Other Non-Cash Items1.04B(1.46B)778M179M(1.17M)
Operating Cash Flow1.43B(728M)1.03B1.6B1.4B
Capital Expenditures(283M)(268M)(272M)(337M)(397M)
Acquisitions (Net)0(45M)(1.89B)00
Purchases of Investments(19M)(17M)(27M)(12M)(11M)
Sales of Investments15M22M26M14M8M
Other Investing Activities682M(45M)(39M)(119M)(195M)
Investing Cash Flow409M(303M)(2.15B)(454M)(595M)
Debt Repayment(1.34B)(1.01B)1.58B(799M)(648.15M)
Common Stock Issued0675M000
Common Stock Repurchased000(26M)0
Dividends Paid00000
Other Financing Activities(173M)(139M)(106M)(43M)(93.85M)
Financing Cash Flow(1.51B)(474M)1.48B(868M)(742M)
Effect of Forex Changes(19M)(23M)9M(36M)61M
Net Change in Cash303M(1.53B)371M239M124M
Free Cash Flow1.14B(996M)760M1.26B1B

Bausch Health Companies Inc.

NYSE:BHC

Intrinsic Alpha fair value

Locked

Current Price

$8.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.